Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

David, a 67-year-old father of three and soon to be first-time grandfather, felt too young to be diagnosed with prostate cancer. "I felt great," he said. "I had no symptoms." David, under the advisement of his oncologist, decided to be treated with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.

1 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Large-scale study on cat intestinal cancer could ultimately benefit humans

A recent, large-scale study on cat intestinal cancer has provided new insight into a common pet disease and its causes; the findings could ultimately benefit humans.

29 Sep 2011

New method for quickly identifying individual viruses

A new method for quickly identifying individual viruses and recognising how they bind to host cells may become a vital tool in the early control of winter vomiting disease and other virus-based diseases. In the west, this means saving money and reducing stress on health-care systems. In developing countries, this means saving lives.

28 Sep 2011

Double balloon enteroscopy safe and effective for detection of small intestine diseases

A large-scale data review by researchers in China of double balloon enteroscopy (DBE) over the last decade showed the endoscopic procedure to be safe and effective for detection of diseases of the small intestine.

27 Sep 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden.

27 Sep 2011

Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Pacira Pharmaceuticals, Inc. today announced that the company's lead investigational product for postsurgical pain management, EXPAREL, was highlighted in the "Hot Topics in Plastic Surgery" panel at the annual scientific assembly of the American Society of Plastic Surgeons (ASPS) in Denver, Colo.

26 Sep 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

Butrans (Buprenorphine) Transdermal System CIII 20 mcg/hour provided significantly lower "average pain over the last 24 hours" scores compared to Butrans 5 mcg/hour when used in opioid-experienced patients with moderate-to-severe chronic low back pain, according to a pivotal Phase 3 clinical study published in the online, August issue of The Journal of Pain.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

Vomiting News and Research

Further Reading

The US Oncology Network affiliate treats advanced prostate cancer patients with PROVENGE

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Large-scale study on cat intestinal cancer could ultimately benefit humans

New method for quickly identifying individual viruses

Double balloon enteroscopy safe and effective for detection of small intestine diseases

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Pacira announces data from EXPAREL clinical study presented at ASPS 2011 meeting

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

The Journal of Pain publishes results from Butrans Transdermal System Phase 3 clinical study

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

African Americans more likely than Caucasians to develop and die from lung cancer

UTHealth doctoral student receives ASM, NIH research fellowships for E. coli study

Common symptoms of pediatric feeding disorder

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News